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Abstract
Background: Approximately 8% of HIV-infected individuals are co-infected with hepatitis B virus (HBV) in sub-Saharan
Africa (SSA). Knowledge of HBV status is important to guide optimal selection of antiretroviral therapy (ART) and
monitor/prevent liver-related complications. We describe changes in testing practices and management of HBV
infection over a 3-year period in HIV clinics across SSA.
Methods: A medical chart review was conducted in large urban HIV treatment centers in Côte d’Ivoire (3 sites), Benin,
Burkina Faso, Cameroon, Kenya, Senegal, South Africa, Togo, Uganda and Zambia (1 site each). Of the patients who
started ART between 2010 and 2012, 100 per year were randomly selected from each clinic. Demographic, clinical and
laboratory information as well as individual treatment histories were collected using a standardized questionnaire. We
examined changes over time in the proportion of patients screened for HBV infection (HBV surface antigen
[HBsAg]-positivity), identified predictors of HBV testing using logistic regression, and assessed the proportion
of patients initiating a tenofovir (TDF)-containing ART regimen.
Results: Overall, 3579 charts of patients initiating ART (64.4% female, median age 37 years) were reviewed in
12 clinics. The proportion of patients screened for HBsAg increased from 17.8% in 2010 to 24.4% in 2012 overall, and
ranged from 0.7% in Kenya to 96% in South Africa. In multivariable analyses, age and region were associated with
HBsAg screening. Among 759 individuals tested, 88 (11.6%; 95% confidence interval [CI] 9.4–14.1) were HBV-infected, of
whom 71 (80.7%) received a TDF-containing ART regimen. HBsAg-positive individuals were twice as likely to receive a
TDF-containing first-line ART regimen compared to HBsAg-negative patients (80.7% vs. 40.3%, p < 0.001). The
proportion of patients on TDF-containing ART increased from 57.9% in 2010 to 90.2% in 2012 in HIV/HBV-co-infected
patients (Chi-2 test for trend: p = 0.01). Only 114 (5.0%) patients were screened for anti-HCV antibodies and one of
them (0.9%, 95% CI 0.02–4.79) had a confirmed HCV infection.
Conclusions: The systematic screening for HBV infection in HIV-positive patients before ART initiation was limited in
most African countries and its uptake varied widely across clinics. Overall, the prescription of TDF increased over time,
with 90% of HIV/HBV-coinfected patients receiving this drug in 2012.
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Background
In sub-Saharan Africa (SSA), approximately 8% of
HIV-infected individuals are hepatitis B surface anti-
gen (HBsAg)-positive [1]. In SSA, most hepatitis B
virus (HBV) infections occur before the age of 5 years
through household contacts [2] and HBV is the single
most important cause of liver disease with attributable
fractions of cirrhosis and hepatocellular carcinoma
reaching 34% and 47%, respectively [3]. However, in
the absence of routine screening in the general popu-
lation, the majority of infected people do not know
their HBV status.
HIV/HBV-coinfected patients are at higher risk of
impaired immunological recovery and hepatotoxicity
during antiretroviral therapy (ART) compared to
HBV-uninfected ones, and overall mortality tends to
be higher in the presence of HBV infection [4–6].
Knowledge of HBV status at ART start is important
for clinical monitoring and to guide the selection of
the initial ART regimen, as tenofovir disoproxil
fumarate (TDF) should be combined with lamivudine
(3TC) or emtricitabine (FTC) and a non-nucleoside
reverse transcriptase inhibitor (NNRTI) in the pres-
ence of HBV infection [7, 8]. Knowledge of HBV
status has other benefits: it helps to guide the choice
of second-line treatment in case of failure of initial
ART or drug toxicity; enables HBV vaccination in
those non-immune; and in pregnant women allows
optimization of prevention of mother-to-child trans-
mission through use of immunoglobulins and antivi-
rals in addition to birth dose of hepatitis B vaccine
and infant vaccination.
Although most international and national ART
guidelines recommend screening for HBV infection
prior to ART initiation, HBV testing uptake has been
poor in most resource-limited settings (RLS). In a
recent analysis of over 60,000 patients initiating ART
in Lusaka, Zambia, the proportion of patients tested
for HBV co-infection increased steadily between
2010 and 2012 but remained below 50% overall and
screening uptake varied widely across clinics [9].
Taking advantage of a large, international HIV co-
hort collaboration in SSA, we aimed to describe
changes in testing practices related to viral hepatitis
over a 3-year period in HIV clinics from ten coun-
tries across SSA. Our main objective was to measure
HBV and hepatitis C virus (HCV) testing uptake in
routine clinical settings. In addition, through stan-
dardized chart extractions we investigated the impact
of HBV infection on the choice of initial ART regi-
men in these settings. A further objective was to
provide insight into current viral hepatitis testing
practices and feasibility challenges in HIV clinics
across SSA to inform international guidelines [10].
Methods
Study settings
We performed a retrospective survey in 12 mostly urban
tertiary hospitals from the following countries in SSA:
Côte d’Ivoire (3 sites), Benin, Burkina Faso, Cameroon,
Kenya, Senegal, South Africa, Togo, Uganda and Zambia
(1 site each), as shown in Fig. 1. All clinics were part of
the International epidemiologic Databases to Evaluate
AIDS (IeDEA) collaboration, a large international
research network of HIV cohorts [11]. The study
received approval from local ethics committees of each
of the ten participating countries:
Study population and data collection
Among the total number of patients who started ART
between 2010 and 2012, we randomly selected a sample
of 100 adults (>18 years) initiating ART per year at each
clinic, i.e. up to 300 patients per clinic in total. If the
number of patients starting ART was smaller than 100
for a given year, all patients were selected for that year.
All demographic and HIV-related clinical data were en-
tered into a local database for clinical care, evaluation
and reporting purposes, within the IeDEA framework.
As information on viral hepatitis screening, monitoring
and treatment were not routinely available in the data
collected by IeDEA, we performed a chart review using
a standardized data collection protocol in all study sites.
In addition to data on screening for HBsAg, anti-HCV
antibody and any other available HBV and HCV sero-
logical and virological tests, we collected information
related to ART history, routinely performed laboratory
tests and HCV treatment.
Statistical analyses
Patient characteristics were presented as medians with
interquartile range (IQR) for continuous variables and
absolute numbers and percentages for categorical ones.
The proportion of people tested and the prevalence of
HBV infection were reported with 95% confidence inter-
vals (CI) overall and by year of ART initiation and coun-
try. The proportion of individuals receiving TDF as part
of their initial ART regimen was evaluated by HBsAg
status. Differences in proportions of HBsAg-positivity
between countries were assessed using Chi-square and
Fisher’s exact tests. Changes in screening uptake over
time were evaluated with a Chi-square test for trend.
We investigated associations between HBsAg testing and
sex, age and region (Central Africa, East Africa, West
Africa and Southern Africa) using logistic regression.
Variables associated with HBsAg screening in univariable
regression (p < 0.20) were included in multivariable
models. All statistical analyses were performed using
Stata 9.0 (StataCorp, College Station, TX, USA).
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Results
Characteristics of clinical sites and patients
A total of 3579 HIV-infected patients were included: 300
per clinic, except in the following sites: Cameroon
(n = 298), Kenya (n = 299), Senegal (n = 297) and
Uganda (n = 285). All clinics were located in urban
settings and the large majority of them were tertiary
health care facilities. Table 1 summarizes patient charac-
teristics at ART initiation, by country. The proportion of
patients from each site included in this study ranged
from 1% in Kenya to 91% in Senegal. The median age
was 37 years (IQR: 31–44) and about two-thirds of pa-
tients (64.4%) were women. For 93.9% of patients, the
first-line ART regimen contained two nucleoside reverse
transcriptase inhibitors (NRTI) and one NNRTI. Overall,
1477 (41.3%) patients started a TDF-containing ART
regimen with the lowest proportion in Benin (13.0%)
and the highest in Zambia (88.3%).
Viral hepatitis screening practices
Overall, 771 patients were tested for HBsAg (21.5%, 95%
CI: 20.2–22.9), with a slight increase of this proportion
over time: 17.8% of individuals started ART in 2010,
21.9% in 2011 and 24.4% in 2012 (p < 0.001; Chi-square
test for trend). HBsAg testing practice varied widely across
countries, from 0.7% tested 2010–2012 in Kenya to 96.0%
tested in South Africa (p < 0.001) (Fig. 2). The proportion
tested remained below 50% in most countries during the
study period with the exception of South Africa where
levels of testing were high throughout, and Zambia,
Senegal and Burkina Faso, where the proportion of pa-
tients tested increased considerably over time (Fig. 2).
Most HBV tests (79.5%) were performed before ART initi-
ation. Fewer than 15 patients were tested in Cameroon,
Burkina Faso and Kenya and only the clinic in South
Africa had a policy of routine HBsAg testing at HIV diag-
nosis. No HBsAg-positive patient had a HBV DNA meas-
urement performed to confirm active HBV infection.
In multivariable analyses, patients over 40 years were
more likely to be tested for HBsAg than younger patients
(adjusted odds ratio [aOR]: 1.20, 95% CI 1.01–1.44), but
sex was not associated with HBV screening (Table 2).
HBsAg screening was more common in Southern Africa
(aOR 33.22, 95% CI 18.23–60.54), East Africa (aOR 4.87,
95% CI 2.62–9.02) and West Africa (aOR 4.20, 95% CI
2.33–7.57) as compared to Central Africa.
Information on HCV testing was available in the files
for 2271 individuals (63.4% of the total study sample).
Overall, only 114 (5.0%) of these patients were tested for
the presence of anti-HCV antibodies. The sites in Kenya,
Zambia and Cameroon did not perform any HCV test-
ing and only sites in Côte d’Ivoire (11 patients, 8.9%),
Burkina Faso (21 patients, 7.0%), Senegal (19 patients,
6.4%) and South Africa (45 patients, 15.0%) tested more
than 10 patients. Only two patients had a positive anti-
HCV result, and one of them was a confirmed HCV
Fig. 1 Geographical distribution of participating sites(Red: West Africa; blue: East Africa; black: Central Africa; green: Southern Africa)
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infection by nucleic acid amplification. Among 114
patients tested for anti-HCV, 110 were also screened
for HBsAg. No patients tested positive for both
HBsAg and anti-HCV.
Prevalence of HBsAg and initial treatment
Among 771 patients screened for HBsAg, 12 results
were not available in the patient charts (2 in Uganda, 1
in Zambia and 9 in South Africa). Of 759 individuals
with HBsAg results, 88 (11.6%; 95% CI 9.4–14.1) had a
positive test. The prevalence of HIV/HBV-co-infection
was 0% in Kenya, 4.3% in Uganda, 4.7% in South Africa,
11.9% in Zambia, 14.3% in Benin, 16.7% in Cameroon,
18.5% in Senegal, 20.0% in Togo, 21.1% in Burkina Faso
and 27.0% in Côte d’Ivoire (p < 0.001).
HBsAg-positive individuals were twice as likely to
receive a TDF-containing first-line ART regimen com-
pared to HBsAg-negative patients (80.7% vs. 40.3%,
p < 0.001 Fig. 3). The proportion of patients on TDF-
containing ART increased from 57.9% in 2010 to 90.2%
in 2012 in HIV/HBV-co-infected patients (Chi-2 test for
trend: p = 0.01) and from 29.2% in 2010 to 51.9% in
2012 in HBV-uninfected individuals (Chi-2 test for
trend: p < 0.001). In West Africa, where TDF was not
part of first-line ART options during the study period,
77.4% of HIV/HBV-co-infected individuals received a
Fig. 2 Changes in HBsAg screening over time, by country (2010–2012)(Red: West Africa; blue: East Africa; black: Central Africa; green: Southern Africa)
Table 1 Characteristics of HIV-infected patients at initiation of antiretroviral therapy in ten African countries, 2010–2012 (N = 3579)
Benin Burkina Faso Cameroon Cote d’Ivoire Kenya Senegal South Africa Togo Uganda Zambia
Number of sites 1 1 1 3 1 1 1 1 1 1
Cities Cotonou Bobo Dioulasso Limbé Abidjan Eldoret Dakar Stellenbosch Lomé Kampala Lusaka
Type of care Tertiary Tertiary Tertiary Primary / Tertiary Tertiary Tertiary Tertiary Tertiary Tertiary Primary
Number of patients included
(proportion of total
population followed)
300
(30%)
300
(21%)
298
(~30%)
900
(20%)
299
(1%)
297
(91%)
300
(16%)
300
(13%)
285
(7%)
300 (~10%)
Median age in years (IQR) 35 (30–42) 35 (30–42) 38 (32–44) 38 (33–45) 37 (32–44) 41 (35–49) 38 (33–46) 35 (30–43) 35 (28–42) 37 (31–42)
Female sex (%) 198 (66.0) 216 (72.0) 196 (65.8) 581 (64.6) 190 (63.5) 179 (60.3) 193 (64.3) 197 (65.7) 191 67.0) 162 (54.0)
Type of ART (%)
2 NRTI +1 NNRTI 298 (99.3) 269 (89.7) 298 (100) 786 (87.3) 291 (97.3) 286 (96.3) 298 (99.3) 287 (95.7) 253 (88.8) 295 (98.3)
3 NRTI 0 (0.0) 0 (0.0) 0 (0.0) 22 (2.5) 0 (0.0) 2 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
2 NRTI +1 PI 2 (0.7) 31 (10.3) 0 (0.0) 92 (10.2) 8 (2.7) 9 (3.0) 2 (0.7) 13 (4.3) 32 (11.2) 5 (1.7)
TDF (%) 39 (13.0) 87 (29.0) 191 (64.1) 303 (33.7) 122 (40.8) 122 (41.1) 243 (81.0) 44 (14.7) 61 (21.4) 265 (88.3)
HBsAg-positivity (%) 5/35 (14.3) 16/76 (21.1) 2/12 (16.7) 10/37 (27.0) 0/2 (0.0) 25/135 (18.5) 13/279 (4.7) 6/30 (20.0) 4/94 (4.3) 7/59 (11.9)
IQR: interquartile range, ART: antiretroviral therapy, NRTI: nucleoside reverse-transcriptase inhibitors, NNRTI: non-nucleoside reverse-transcriptase
Inhibitors, PI: protease inhibitors, TDF: tenofovir; HBsAg: Hepatitis B surface antigen
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TDF-containing regimen, whereas this was only the case
for 26.9% of HBV-uninfected ones.
Discussion
Despite the consistent recommendation in national and
international HIV guidelines to test all HIV-infected
patients for HBV-coinfection before ART initiation,
screening uptake was generally poor in this study of 12
large urban tertiary hospitals in SSA. Of over 3500 HIV-
infected individuals from ten African countries, less than
one-quarter was tested for the presence of HBV infec-
tion. In most sites, HBsAg testing uptake increased only
minimally between 2010 and 2012, with large differences
in the proportion of patients tested across clinics and
countries. None of the 88 HIV/HBV-co-infected patients
in this sample had an HBV viral load test performed
after a positive HBsAg test. However, the majority of
HIV/HBV-co-infected patients initiated a standard-of-
care TDF-containing ART regimen.
The implementation of HBV testing practices for HIV-
infected patients was sub-optimal in the majority of the
clinical sites assessed. The South African clinic was the
only one to achieve near-complete HBV testing rates
throughout the study period, reflecting a local policy of
routine HBsAg testing at diagnosis, and a clear improve-
ment in testing uptake over time was only seen in the
sites in Burkina Faso, Senegal and Zambia. The limited
availability of HBsAg and anti-HCV screening shown in
Table 2 Factors associated with hepatitis B screening among HIV-infected patients in ten African countries, 2010–2012 (N = 3579)
Univariable analysis Multivariable analysis
n / N (%) OR 95% CI P aOR 95% CI P
Age in years (%) 0.09 0.04
≤ 40 469 / 2270 (20.7) Ref. – Ref. –
> 40 302 / 1309 (23.1) 1.15 0.98–1.36 1.20 1.01–1.44
Sex (%) 0.55
Female 489 / 2303 (21.2) Ref. –
Male 282 / 1276 (22.1) 1.05 0.89–1.24
African region (%) <0.001 <0.001
Central 12 / 298 (4.0) Ref. Ref.
West 313 / 2097 (14.9) 4.18 2.32–7.54 4.20 2.33–7.57
East 98 / 584 (16.8) 4.81 2.59–8.91 4.87 2.62–9.02
South 348 / 600 (58.0) 32.90 18.07–59.96 33.22 18.23–60.54
n: number of patients screened for HBV; N: total number of patients; OR: odds ratio; aOR: adjusted odds ratio;
CI: confidence interval; P: p-value
Fig. 3 Proportion of patients on tenofovir-based regimens, by year and HBsAg status in ten sub-Saharan African countries, 2010–2012. Others:
HbsAg-negative or not screened
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our study reflects a missed opportunity as the popula-
tion studied is already engaged in HIV care and testing
would likely be acceptable to most patients. There are
several potential barriers to more widespread adoption
of testing for viral hepatitis in SSA, including financial
reasons (the costs of rapid tests and nucleic acid testing
are rarely covered by national HIV programs or donor
agencies); logistical reasons (poor availability of quality-
assured rapid tests in most clinics), and lack of clear
national guidance on testing strategies [12]. There is also
an emerging view that with the increasing use of TDF-
based ART as the preferred first-line regimen, the major-
ity of HBV-coinfected patients will receive effective
suppressive treatment and HBsAg testing is no longer
required. However, knowledge of HBsAg status is
particularly important when switching to second-line
ART for treatment failure or drug toxicity to ensure that
the new regimen continues to be effective against HBV
and avoid the risk of flare [13]. Whereas health dispar-
ities in access to care for liver diseases in SSA are well
documented [14], similar system-related barriers to viral
hepatitis testing have been underlined in a recent report
for Europe [15]. Thus, there is an urgent need to
improve access to simple and cheap diagnostic tests for
HBV and HCV infection globally, a goal that can only be
achieved by translating international guidelines into
national strategies and increased political will and
resources [16]. Improvements in blood safety in SSA
illustrate that with adequate funding mechanisms and a
well-defined global policy high success rates are achiev-
able: the proportion of countries testing at least 95% of
blood donations for HBsAg increased from 76% to 94%
in the last decade [17].
As expected in settings where HBsAg testing was lim-
ited, additional hepatitis diagnostic testing was uncom-
mon. Indeed, due to high cost and limited laboratory
capacities in most sites, HBV DNA measurement was
unavailable. The use of dried blood spots for HBV viral
load measurements [18], and less expensive nucleic acid
amplification techniques should improve uptake of con-
firmatory HBV viral load testing in the future. HCV
screening was unavailable in most settings and only
performed in highly selected groups of patients. More
than 75% of HCV test results came from the cohorts in
South Africa, Senegal and Burkina Faso, where access to
HCV testing was improved by the presence of specific-
ally trained laboratory personnel. Overall only two
patients had a positive anti-HCV test, in line with recent
data from Zambia and Mozambique which highlighted
the low prevalence of HCV infection in southern Africa
[19]. However, as the burden of HCV infection in HIV-
positive people varies widely across African sub-regions
[20], HCV testing strategies should be tailored to the
local epidemiological context, including routine testing
in high prevalence settings and focused testing in HIV-
infected high-risk groups such as persons who inject
drugs, men who have sex with men, sex workers and
prisoners, as well as children of HIV/HCV-co-infected
women.
The prevalence of HBV-infection (11.6%) in our study
probably overestimated the true population prevalence
among people living with HIV: several clinics had more
than 20% of patients with a positive HBsAg test, most
likely because patients with clinical features of liver
disease were more likely to be tested than asymptomatic
patients. This is also reflected by the lower HBV-
prevalence found in South Africa, where systematic
screening was performed. Importantly, the proportion of
HIV/HBV-co-infected individuals who received a
standard-of-care TDF-containing regimen increased over
time. Considering that over two-thirds of HBV infec-
tions were diagnosed in West African sites where TDF
was not part of the preferred first-line ART regimens
during the study period, it is encouraging to note that by
2012, 90% of HBV-infected patients had TDF included
in their initial ART regimen, irrespective of clinic or
country. Conversely, HBsAg-negative patients were less
likely to receive TDF, reflecting the national treatment
guidelines during the study period. By 2012, 80% of low-
and middle-income countries globally had adopted the
2010 World Health Organization (WHO) guidelines and
began the transition away from stavudine to TDF or
zidovudine (AZT) for all new ART initiations [21]. How-
ever, progress in the uptake of TDF as part of the
preferred first-line ART has been variable across coun-
tries: whereas Zambia started to include TDF in first-
line ART in 2007, many West African countries were
still using AZT in first-line ART at the end of 2012. In
fact, most countries in West Africa only started the
implementation of TDF in first-line ART in 2015.
This is the largest study to date assessing HBV and
HCV screening practices in routine clinical HIV care
settings in SSA. It was nested within an established
observational data collection platform (the IeDEA
network) and utilized standardized data collection
instruments at all sites for chart review. Unfortu-
nately, we could not obtain more detailed information
on demographic factors such as education level or
employment, as these data were not reported identi-
cally in the charts of most clinics. Socioeconomic fac-
tors could well have played a role in access to HBV
and HCV screening in our study, especially in settings
where no systematic testing was performed. A further
limitation of our study was the absence of data on
the reasons for HBV testing for the majority of
patients, except for the South African clinic which
had a documented policy of screening all patients
during the study period. As a consequence, we could
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not determine the proportion of patients who were
tested due to clinical signs of liver disease, which
potentially led to an over-estimation of HBsAg preva-
lence. In addition, we may have under-estimated the
proportion of HBV-coinfected patients in our study as
we would not have diagnosed patients with occult
HBV infection, which is expected to be present in
10%–15% of HIV-infected individuals in SSA [22, 23].
Finally, as only large urban clinics were selected for
this study, our results may not be generalizable to
rural areas. Indeed, HBV and HCV testing is likely to
be even more limited in rural settings.
In summary, our results highlight the heterogeneity
in HBsAg testing and the near-absence of HCV testing
for HIV-infected individuals in SSA. As the availability
of TDF for long-term treatment of HBV infection and
direct-acting antivirals for HCV infection is increasing
globally, early diagnosis of HBV and, in specific risk
groups, of HCV infections is of utmost importance.
The WHO hepatitis testing guidelines recommend
focused testing for HBV and HCV in most affected
populations that include HIV-infected persons [10].
They also recommend that hepatitis testing should
make use of existing opportunities and infrastructure
for testing that include health facility and community-
based testing for HIV. The availability of polyvalent
platforms will allow increasingly for multiplex testing
for HBV, HCV, HIV and syphilis. HIV programs
should consider adopting HBsAg testing uptake as a
metric for program evaluation and surveys similar to
this one should be repeated regularly to monitor
progress, including in rural areas. Finally, in order to
improve current testing practices, more efforts are
needed to understand the main reasons for the limited
uptake of HBV and HCV diagnostic practices in many
low-income settings.
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